ALLAKOS INC (ALLK) Stock Price, Quote, News and Overview
NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD
ALLK Quote, Performance and Key Statistics
0.3291
0 (-0.06%)
The current stock price of ALLK is 0.3291 USD. In the past month the price increased by 1.89%. In the past year, price decreased by -77.15%.
ALLK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.42 | 334.13B | ||
| AMGN | AMGEN INC | 13.97 | 155.93B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.57B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.68 | 55.89B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.64B | ||
| ARGX | ARGENX SE - ADR | 101.5 | 35.64B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.75 | 28.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.20B | ||
| NTRA | NATERA INC | N/A | 22.42B | ||
| BIIB | BIOGEN INC | 8.48 | 19.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.01B |
Related stock screener links
About ALLK
Company Profile
Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 61 full-time employees. The company went IPO on 2018-07-19. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The firm is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Company Info
ALLAKOS INC
825 Industrial Road, Suite 500
San Carlos CALIFORNIA 94065 US
CEO: Robert Alexander
Employees: 131
Phone: 16505975002
ALLAKOS INC / ALLK FAQ
What is the stock price of ALLAKOS INC today?
The current stock price of ALLK is 0.3291 USD. The price decreased by -0.06% in the last trading session.
What is the ticker symbol for ALLAKOS INC stock?
The exchange symbol of ALLAKOS INC is ALLK and it is listed on the Nasdaq exchange.
On which exchange is ALLK stock listed?
ALLK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALLAKOS INC stock?
10 analysts have analysed ALLK and the average price target is 1.26 USD. This implies a price increase of 282.25% is expected in the next year compared to the current price of 0.3291. Check the ALLAKOS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALLAKOS INC worth?
ALLAKOS INC (ALLK) has a market capitalization of 29.74M USD. This makes ALLK a Nano Cap stock.
How many employees does ALLAKOS INC have?
ALLAKOS INC (ALLK) currently has 131 employees.
What are the support and resistance levels for ALLAKOS INC (ALLK) stock?
ALLAKOS INC (ALLK) has a support level at 0.32. Check the full technical report for a detailed analysis of ALLK support and resistance levels.
Should I buy ALLAKOS INC (ALLK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALLK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALLK, evaluating the profitability, health, valuation and growth aspects
- ALLAKOS INC (ALLK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALLAKOS INC (ALLK) Sales and EPS estimates to see what analysts future expectations are.
- ALLAKOS INC (ALLK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALLAKOS INC (ALLK) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALLAKOS INC (ALLK) Stock Chart to make your own analysis
- ALLAKOS INC (ALLK) Latest news and press-releases to stay up to date.
Does ALLAKOS INC (ALLK) stock pay dividends?
ALLK does not pay a dividend.
When does ALLAKOS INC (ALLK) report earnings?
ALLAKOS INC (ALLK) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of ALLAKOS INC (ALLK)?
ALLAKOS INC (ALLK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
What is the Short Interest ratio of ALLAKOS INC (ALLK) stock?
The outstanding short interest for ALLAKOS INC (ALLK) is 0.51% of its float. Check the ownership tab for more information on the ALLK short interest.
ALLK Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALLK. When comparing the yearly performance of all stocks, ALLK is a bad performer in the overall market: 89.24% of all stocks are doing better.
ALLK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLK. ALLK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALLK Financial Highlights
Over the last trailing twelve months ALLK reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 67.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.89% | ||
| ROE | -146.95% | ||
| Debt/Equity | 0 |
ALLK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to ALLK. The Buy consensus is the average rating of analysts ratings from 10 analysts.